Skip to main content
SpringerLink
Log in

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma

  • Case Report
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

We used regimens containing rituximab in the treatment of five hepatitis B virus surface antibody (HBsAb)-positive patients with non-Hodgkin's lymphoma (NHL). Serum levels of HBsAb were obtained and analyzed in four of these patients. Two patients were HBs antigen (HBsAg) positive. One of these HBsAg-positive patients was treated with lamivudine because the patient developed fulminant hepatitis from hepatitis B virus (HBV) infection prior to chemotherapy. However, none of the other patients were administered lamivudine. An HBsAg-positive patient who did not receive lamivudine treatment later developed fulminant hepatitis. Another HBsAg-positive patient receiving lamivudine prophylaxis did not develop severe hepatitis arising from HBV. In the three patients not receiving lamivudine treatment, serum HBsAb titers decreased soon after the administration of rituximab. These results suggest that rituximab reduced the antibody titer for HBV, thus inducing an immunological environment leading to easy reactivation of HBV. Lamivudine prophylaxis was effective, at least when rituximab was given to an HBsAg-positive patient with non-Hodgkin's lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

References

  1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    CAS  PubMed  Google Scholar 

  2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    CAS  PubMed  Google Scholar 

  3. Tobinai K, Kobayasi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T, and Members of the IDCE-C2B8 Study Group (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in a relapsed B-cell lymphoma. Ann Oncol 9:527–534

    CAS  PubMed  Google Scholar 

  4. Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, Kagami Y, Kinoshita T, Kasai M, Kiyama Y, Kobayashi Y, Tobinai K, and Members of the IDEC-C2B8 Study Group (2001) Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 73:213–221

    CAS  PubMed  Google Scholar 

  5. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994 ) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457–2466

    CAS  PubMed  Google Scholar 

  6. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lobuglio AF, Jonas C, Kippenstein D, Dallire B, Varns C (1999) Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276

    PubMed  Google Scholar 

  7. Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68–69

    Article  CAS  Google Scholar 

  8. Ng HJ, Lim LC (2001) Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 80:549–552

    Article  CAS  PubMed  Google Scholar 

  9. Skrabs C, Muller C, Agis H, Mannhalter C, Jager U (2002) Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 16:1884-1886

    Article  CAS  PubMed  Google Scholar 

  10. Jager G, Neumeister P, Brezinschek R, Hofler G, Quehenberger F, Linkesch W, Sill H (2002) Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol 69:21–26

    Article  PubMed  Google Scholar 

  11. Domingo-Domenech E,Gonzalez-Barca E, Estany C, Sureda A, Besalduch J, de Sevilla AF (2002) Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica 87:1229–1230

    Google Scholar 

  12. Rossini F, Capalbo S, Fumagalli M, Battista C, de Santis G, Bolis S, Montesano R, Liso V, Pogliani EM (2002) "Standard dose"; rituximab in refractory chronic lymphocytic leukemia. Hematol J 3 [Suppl 1]:827

  13. Mimidis K, Tsatalas C, Margaritis D, Martinis G, Spanoudakis E, Kotsiou S, Kartalis G, Bourikas G (2002) Efficacy of lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol 107:49–51

    Article  CAS  PubMed  Google Scholar 

  14. Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, Mutou Y (2001) Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 68:292-294

    Article  CAS  PubMed  Google Scholar 

  15. Kami M, Hamaki T, Murashige N, Kishii Y, Kusumi E, Yuji K, Miyakoshi S, Ueyama J, Morinaga S, Mutou Y (2003) Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J 4:159–162

    Article  CAS  PubMed  Google Scholar 

  16. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Tood D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 100:182–188

    CAS  PubMed  Google Scholar 

  17. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunol 24:263–271

    Article  CAS  Google Scholar 

  18. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E (2002) Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 50:95–99

    Article  CAS  PubMed  Google Scholar 

  19. Al-Taie OH, Mork H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M (1999) Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol 78:247–249

    CAS  PubMed  Google Scholar 

  20. Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, Fanin R, Baccarani M (2000) Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108:394–396

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hakodate Municipal Hospital 1–10–1, 041–0821, Minato-cho, Hakodate, Japan

    Y. Tsutsumi, T. Kawamura, T. Miura, H. Kanamori & N. Masauzi

  2. Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    J. Tanaka & M. Imamura

  3. Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    M. Asaka

Authors
  1. Y. Tsutsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Obara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Asaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. Masauzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Tsutsumi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsutsumi, Y., Tanaka, J., Kawamura, T. et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83, 58–60 (2004). https://doi.org/10.1007/s00277-003-0748-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0748-4

Keywords

Search

Navigation